Hosted on MSN

DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 Approval

DexCom DXCM is facing regulatory scrutiny following a warning letter recently posted by the FDA. This could affect the approval of the company’s upcoming 15-day G7 continuous glucose monitor (CGM).
Hosted on MSN

DexCom CGM Sensor Sales to Continue Despite FDA Warning Letter

DexCom DXCM received a warning letter from the FDA on March 4, 2025, following inspections of its San Diego and Mesa facilities in 2024. The FDA cited deficiencies in the company’s manufacturing ...
MobiHealthNews

FDA approves Dexcom's CGM accessory app days after relevant draft guidance

Dexcom has received approval from the FDA for a new version of its smartphone connected Dexcom Share platform that will eliminate the docking cradle and allow a patient's continuous glucose monitor ...
Healio

Next-generation CGM with 15-day sensor improves upon previous generation’s accuracy

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The 15-day Dexcom G7 had a MARD of 8%, a small ...